Glioblastoma entities express subtle differences in molecular composition and response to treatment

Glioblastoma (GBM) is a grade IV astrocytoma. GBM patients show resistance to chemotherapy such as temozolomide (TMZ), the gold standard treatment. In order to simulate the molecular mechanisms behind the different chemotherapeutic responses in GBM patients we compared the cellular heterogeneity and...

Descripción completa

Detalles Bibliográficos
Autores principales: Balça-Silva, Joana, Matias, Diana, Do Carmo, Anália, Dubois, Luiz Gustavo, Gonçalves, Ana Cristina, Girão, Henrique, Silva Canedo, Nathalie Henriques, Correia, Ana Helena, De Souza, Jorge Marcondes, Sarmento-Ribeiro, Ana Bela, Lopes, Maria Celeste, Moura-Neto, Vivaldo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549060/
https://www.ncbi.nlm.nih.gov/pubmed/28714013
http://dx.doi.org/10.3892/or.2017.5799

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549060/
https://www.ncbi.nlm.nih.gov/pubmed/28714013
http://dx.doi.org/10.3892/or.2017.5799

Ejemplares similares